Elsevier Launches New Open Access Journal – NeuroImage: Clinical

London, September 26, 2012 –  Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the launch of NeuroImage: Clinical, a new open access journal, and sister journal to NeuroImage.

NeuroImage: Clinical provides a vehicle for communicating important advances in the study of abnormal structure-function relationships of the human nervous system based on imaging. It offers authors the choice of two Creative Commons licenses, either  Creative Commons By Attribution or  Creative Commons by Attribution-NonCommercial-ShareAlike.

Paul Fletcher, MD, Bernard Wolfe Professor of Health Neuroscience at the University of Cambridge, UK, and co-Editor-in-Chief said of the journal launch, "With the growing importance of clinical neuroimaging, we hope that the new journal can serve the field by publishing innovative, high quality studies, reviews and opinions - work that may ultimately prove valuable in informing and improving clinical practice."

Scott Grafton, MD, Professor of Psychology and Director of the Imaging Center at the University of California, Santa Barbara, also co-Editor-in-Chief added, “NeuroImage: Clinical provides an unprecedented opportunity to publish novel insights into the pathophysiology of nervous system disease based on cutting-edge methods of imaging and analysis.”

Michael Osuch, Executive Publisher at Elsevier said, “In recent years, advances in the field of neuroimaging have enabled more robust clinical research studies to be undertaken, and opened up the potential for translating these applications into having a direct impact in both diagnosis and treatment of neuropsychiatric diseases. This new launch will provide the community with a high quality journal in which to publish these advances.”

For more information or to submit an article, go to  NeuroImage: Clinical. First articles to be published in the journal are now available online through ScienceDirect.

# # #

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including  The Lancet and  Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include  ScienceDirect Scopus Reaxys ClinicalKey and  Mosby’s Nursing Suite, which enhance the productivity of science and health professionals, and the  SciVal suite and  MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam,  Elsevier employs 7,000 people worldwide. The company is part of  Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Michael Osuch
Elsevier
+44 20 7424 4321
michael.osuch@elsevier.com